Total Payments
$156,014
2024 Payments
$4,960
Companies
16
Transactions
104
Medicare Patients
1,051
Medicare Billing
$174,995
Payment Breakdown by Category
Other$74,608 (47.8%)
Consulting$62,230 (39.9%)
Travel$10,606 (6.8%)
Research$5,563 (3.6%)
Education$1,898 (1.2%)
Food & Beverage$1,111 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $62,230 | 56 | 39.9% |
| Grant | $54,706 | 2 | 35.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $19,902 | 9 | 12.8% |
| Travel and Lodging | $10,606 | 11 | 6.8% |
| Unspecified | $5,563 | 4 | 3.6% |
| Education | $1,898 | 1 | 1.2% |
| Food and Beverage | $1,111 | 21 | 0.7% |
Payments by Type
General
$150,452
100 transactions
Research
$5,563
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Baxter Healthcare | $62,503 | 50 | $0 (2024) |
| Medtronic Vascular, Inc. | $54,706 | 2 | $0 (2019) |
| Travere Therapeutics, Inc. | $8,238 | 13 | $0 (2023) |
| AstraZeneca UK Limited | $8,200 | 5 | $0 (2023) |
| AbbVie, Inc. | $4,600 | 3 | $0 (2017) |
| Astute Medical, Inc. | $3,817 | 11 | $0 (2022) |
| Retrophin, Inc. | $3,033 | 5 | $0 (2019) |
| GENZYME CORPORATION | $3,002 | 2 | $0 (2020) |
| CALLIDITAS THERAPEUTICS US INC. | $2,504 | 2 | $0 (2024) |
| Jazz Pharmaceuticals Inc. | $2,050 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,960 | 7 | CALLIDITAS THERAPEUTICS US INC. ($2,504) |
| 2023 | $3,181 | 3 | AstraZeneca UK Limited ($2,400) |
| 2022 | $12,209 | 13 | AstraZeneca UK Limited ($5,800) |
| 2021 | $8,877 | 11 | Baxter Healthcare ($5,865) |
| 2020 | $15,645 | 14 | BAXTER HEALTHCARE ($8,330) |
| 2019 | $61,541 | 33 | BAXTER HEALTHCARE ($33,252) |
| 2018 | $6,835 | 9 | BAXTER HEALTHCARE ($4,071) |
| 2017 | $42,766 | 14 | Medtronic Vascular, Inc. ($30,000) |
All Payment Transactions
104 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/07/2024 | Baxter Healthcare | Renal - Theranova (Device) | Consulting Fee | Cash or cash equivalent | $2,200.00 | General |
| Category: Renal | ||||||
| 11/01/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Consulting Fee | Cash or cash equivalent | $2,500.00 | General |
| Category: Nephrology | ||||||
| 10/24/2024 | Baxter Healthcare | Renal - Theranova (Device) | Food and Beverage | In-kind items and services | $125.77 | General |
| Category: Renal | ||||||
| 10/24/2024 | Baxter Healthcare | Renal - Theranova (Device) | Food and Beverage | In-kind items and services | $45.24 | General |
| Category: Renal | ||||||
| 10/10/2024 | Becton, Dickinson and Company | Site-Rite (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $27.00 | General |
| Category: Catheter Care and Medication Delivery | ||||||
| 09/27/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $58.61 | General |
| Category: Immunology | ||||||
| 04/15/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $3.69 | General |
| Category: Nephrology | ||||||
| 09/01/2023 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| 05/30/2023 | Travere Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $350.00 | General |
| 03/03/2023 | Baxter Healthcare | Renal - Sharesource (Device) | Consulting Fee | Cash or cash equivalent | $431.25 | General |
| Category: Renal | ||||||
| 12/08/2022 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $1,400.00 | General |
| 12/08/2022 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $1,400.00 | General |
| 11/18/2022 | Travere Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| 11/18/2022 | Travere Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| 11/15/2022 | Astute Medical, Inc. | NEPHROCHECK Liquid Control Kit (Device) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: Diagnostics | ||||||
| 11/15/2022 | Astute Medical, Inc. | NEPHROCHECK Liquid Control Kit (Device) | Consulting Fee | Cash or cash equivalent | $416.67 | General |
| Category: Diagnostics | ||||||
| 11/15/2022 | Astute Medical, Inc. | NEPHROCHECK Liquid Control Kit (Device) | Consulting Fee | Cash or cash equivalent | $250.00 | General |
| Category: Diagnostics | ||||||
| 08/11/2022 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $1,600.00 | General |
| 08/11/2022 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $1,400.00 | General |
| 06/13/2022 | Travere Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| 06/13/2022 | Travere Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| 03/09/2022 | Alexion Pharmaceuticals, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $200.00 | General |
| 01/26/2022 | Baxter Healthcare | Renal - PD (Device) | Consulting Fee | Cash or cash equivalent | $2,242.50 | General |
| Category: Renal | ||||||
| 12/17/2021 | Baxter Healthcare | Renal - PD (Device) | Education | Cash or cash equivalent | $1,897.50 | General |
| Category: Renal | ||||||
| 11/29/2021 | Baxter Healthcare | Renal - PD (Device) | Consulting Fee | Cash or cash equivalent | $2,242.50 | General |
| Category: Renal | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| M11-352 | AbbVie, Inc. | $4,600 | 3 |
| LAPIS Trial: A Biomarker-Guided Implementation of Kidney-Sparing Care Measures to Prevent AKI in Sepsis Patients | bioMerieux | $962.50 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 268 | 457 | $157,355 | $39,718 |
| 2022 | 8 | 270 | 446 | $144,354 | $44,525 |
| 2021 | 10 | 310 | 553 | $166,493 | $53,790 |
| 2020 | 8 | 203 | 377 | $121,639 | $36,962 |
Total Patients
1,051
Total Services
1,833
Medicare Billing
$174,995
Procedure Codes
33
All Medicare Procedures & Services
33 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90966 | Home dialysis services per month (20 years or older) | Office | 2023 | 24 | 62 | $46,190 | $14,109 | 30.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 48 | 122 | $24,766 | $7,380 | 29.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 42 | 72 | $21,141 | $6,561 | 31.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 76 | 116 | $37,564 | $5,320 | 14.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 25 | 25 | $14,175 | $3,447 | 24.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 42 | 49 | $11,264 | $2,195 | 19.5% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 11 | 11 | $2,255 | $706.75 | 31.3% |
| 90966 | Home dialysis services per month (20 years or older) | Office | 2022 | 24 | 78 | $44,616 | $18,177 | 40.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 65 | 90 | $27,090 | $6,708 | 24.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 31 | 69 | $19,992 | $5,573 | 27.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 43 | 81 | $16,308 | $4,452 | 27.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 53 | 57 | $11,697 | $2,722 | 23.3% |
| 90945 | Dialysis procedure including 1 evaluation | Facility | 2022 | 21 | 38 | $7,980 | $2,645 | 33.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 15 | 15 | $8,441 | $2,379 | 28.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 18 | 18 | $8,230 | $1,870 | 22.7% |
| 90966 | Home dialysis services per month, patient 20 years of age or older | Office | 2021 | 27 | 104 | $59,488 | $23,970 | 40.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 61 | 138 | $27,315 | $7,851 | 28.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 58 | 72 | $20,007 | $5,090 | 25.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 30 | 51 | $14,448 | $4,166 | 28.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 70 | 81 | $16,225 | $3,974 | 24.5% |
| 90945 | Dialysis procedure including one evaluation | Facility | 2021 | 11 | 48 | $10,080 | $3,337 | 33.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 15 | 15 | $8,268 | $2,403 | 29.1% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 13 | 13 | $5,450 | $1,414 | 25.9% |
| 90935 | Hemodialysis procedure with one physician evaluation | Facility | 2021 | 12 | 18 | $4,050 | $1,056 | 26.1% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2021 | 13 | 13 | $1,162 | $529.09 | 45.5% |
About Mitchell Rosner
Mitchell Rosner is a Nephrology healthcare provider based in Charlottesville, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1164591707.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Mitchell Rosner has received a total of $156,014 in payments from pharmaceutical and medical device companies, with $4,960 received in 2024. These payments were reported across 104 transactions from 16 companies. The most common payment nature is "Consulting Fee" ($62,230).
As a Medicare-enrolled provider, Rosner has provided services to 1,051 Medicare beneficiaries, totaling 1,833 services with total Medicare billing of $174,995. Data is available for 4 years (2020–2023), covering 33 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Location Charlottesville, VA
- Active Since 11/07/2006
- Last Updated 08/11/2023
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1164591707
Products in Payments
- Renal - PD (Device) $27,800
- Renal - Sharesource (Device) $24,410
- Renal - Non Product Related (Biological) $4,452
- TARPEYO (Drug) $2,504
- Renal - Theranova (Device) $2,371
- Defitelio (Drug) $2,050
- TOLVAPTAN (Drug) $1,939
- Renal - Amia (Device) $1,338
- Renal - Chronic (Device) $1,190
- NEPHROCHECK Liquid Control Kit (Device) $1,167
- NEPROCHECK (Device) $962.50
- Renal - Revaclear (Device) $862.00
- NEPHROCHECK TEST (Device) $650.00
- THYMOGLOBULIN (Drug) $125.00
- Renal - Acute (Device) $79.99
- Fabhalta (Drug) $58.61
- Site-Rite (Device) $27.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Charlottesville
Rasheed Balogun, M.d, M.D
Nephrology — Payments: $11,685
Nephrology $11,685
Mark Okusa, M.d, M.D
Nephrology — Payments: $9,688
Nephrology $9,688
John Barcia, Md, MD
Nephrology — Payments: $2,166
Nephrology $2,166
Ross Isaacs, M.d, M.D
Nephrology — Payments: $1,077
Nephrology $1,077
Uta Erdbruegger, Md, MD
Nephrology — Payments: $729.85
Nephrology $729.85
Amanda Renaghan, M.d, M.D
Nephrology — Payments: $312.27
Nephrology $312.27